Notice: TimeXNet Web will be temporarily affected due to Human Genome Center server maintenance until February 21 (Wednesday) 09:00 JST.
Job Name:
Response of Myeloma Cells to Chemotherapy
Current Gene List:
Background List:
Submitted Network
Note: Only the top 1000 records are shown here
| Category | Term | Genes | Count | % | P-value | Benjamini |
|---|---|---|---|---|---|---|
| KEGG_PATHWAY | hsa05200:Pathways in cancer | 270 | 14.5 | 7.0e-81 | 1.8e-78 | |
| KEGG_PATHWAY | hsa04151:PI3K-Akt signaling pathway | 233 | 12.5 | 7.4e-68 | 9.7e-66 | |
| KEGG_PATHWAY | hsa05161:Hepatitis B | 128 | 6.9 | 8.0e-60 | 6.9e-58 | |
| KEGG_PATHWAY | hsa05166:HTLV-I infection | 183 | 9.8 | 3.2e-58 | 2.1e-56 | |
| KEGG_PATHWAY | hsa05205:Proteoglycans in cancer | 150 | 8.1 | 7.4e-53 | 3.9e-51 | |
| KEGG_PATHWAY | hsa04722:Neurotrophin signaling pathway | 101 | 5.4 | 3.1e-45 | 1.3e-43 | |
| KEGG_PATHWAY | hsa04062:Chemokine signaling pathway | 132 | 7.1 | 7.9e-43 | 2.9e-41 | |
| KEGG_PATHWAY | hsa04510:Focal adhesion | 142 | 7.6 | 1.6e-42 | 5.1e-41 | |
| KEGG_PATHWAY | hsa04915:Estrogen signaling pathway | 87 | 4.7 | 3.7e-42 | 1.1e-40 | |
| KEGG_PATHWAY | hsa04728:Dopaminergic synapse | 103 | 5.5 | 1.5e-41 | 3.9e-40 | |
| KEGG_PATHWAY | hsa05215:Prostate cancer | 80 | 4.3 | 6.3e-40 | 1.5e-38 | |
| KEGG_PATHWAY | hsa04014:Ras signaling pathway | 147 | 7.9 | 6.8e-40 | 1.5e-38 | |
| KEGG_PATHWAY | hsa04015:Rap1 signaling pathway | 139 | 7.5 | 8.4e-39 | 1.7e-37 | |
| KEGG_PATHWAY | hsa04114:Oocyte meiosis | 88 | 4.7 | 5.1e-38 | 9.5e-37 | |
| KEGG_PATHWAY | hsa05142:Chagas disease (American trypanosomiasis) | 88 | 4.7 | 2.5e-37 | 4.3e-36 | |
| KEGG_PATHWAY | hsa04914:Progesterone-mediated oocyte maturation | 76 | 4.1 | 7.3e-36 | 1.2e-34 | |
| KEGG_PATHWAY | hsa04380:Osteoclast differentiation | 99 | 5.3 | 5.7e-35 | 8.7e-34 | |
| KEGG_PATHWAY | hsa04010:MAPK signaling pathway | 154 | 8.3 | 7.2e-35 | 1.0e-33 | |
| KEGG_PATHWAY | hsa04660:T cell receptor signaling pathway | 84 | 4.5 | 1.7e-34 | 2.3e-33 | |
| KEGG_PATHWAY | hsa05220:Chronic myeloid leukemia | 67 | 3.6 | 2.7e-34 | 3.5e-33 | |
| KEGG_PATHWAY | hsa05162:Measles | 99 | 5.3 | 5.5e-34 | 6.9e-33 | |
| KEGG_PATHWAY | hsa04024:cAMP signaling pathway | 127 | 6.8 | 2.1e-33 | 2.5e-32 | |
| KEGG_PATHWAY | hsa05169:Epstein-Barr virus infection | 122 | 6.6 | 2.8e-33 | 3.1e-32 | |
| KEGG_PATHWAY | hsa04620:Toll-like receptor signaling pathway | 84 | 4.5 | 2.9e-33 | 3.1e-32 | |
| KEGG_PATHWAY | hsa04668:TNF signaling pathway | 86 | 4.6 | 3.9e-33 | 4.0e-32 | |
| KEGG_PATHWAY | hsa05164:Influenza A | 113 | 6.1 | 3.7e-32 | 3.7e-31 | |
| KEGG_PATHWAY | hsa04713:Circadian entrainment | 77 | 4.1 | 5.0e-32 | 4.8e-31 | |
| KEGG_PATHWAY | hsa04910:Insulin signaling pathway | 98 | 5.3 | 1.2e-31 | 1.1e-30 | |
| KEGG_PATHWAY | hsa04012:ErbB signaling pathway | 73 | 3.9 | 3.4e-31 | 3.0e-30 | |
| KEGG_PATHWAY | hsa05214:Glioma | 59 | 3.2 | 1.2e-30 | 1.1e-29 | |
| KEGG_PATHWAY | hsa05203:Viral carcinogenesis | 119 | 6.4 | 1.4e-30 | 1.2e-29 | |
| KEGG_PATHWAY | hsa05206:MicroRNAs in cancer | 99 | 5.3 | 2.1e-30 | 1.7e-29 | |
| KEGG_PATHWAY | hsa05152:Tuberculosis | 113 | 6.1 | 2.5e-30 | 1.9e-29 | |
| KEGG_PATHWAY | hsa05221:Acute myeloid leukemia | 54 | 2.9 | 6.6e-30 | 5.1e-29 | |
| KEGG_PATHWAY | hsa04630:Jak-STAT signaling pathway | 100 | 5.4 | 2.9e-29 | 2.2e-28 | |
| KEGG_PATHWAY | hsa05168:Herpes simplex infection | 114 | 6.1 | 4.5e-29 | 3.3e-28 | |
| KEGG_PATHWAY | hsa04912:GnRH signaling pathway | 72 | 3.9 | 9.7e-29 | 6.8e-28 | |
| KEGG_PATHWAY | hsa05160:Hepatitis C | 93 | 5.0 | 2.1e-28 | 1.4e-27 | |
| KEGG_PATHWAY | hsa04720:Long-term potentiation | 58 | 3.1 | 3.5e-28 | 2.3e-27 | |
| KEGG_PATHWAY | hsa05145:Toxoplasmosis | 85 | 4.6 | 4.8e-28 | 3.1e-27 | |
| KEGG_PATHWAY | hsa05213:Endometrial cancer | 50 | 2.7 | 1.6e-27 | 1.0e-26 | |
| KEGG_PATHWAY | hsa04725:Cholinergic synapse | 82 | 4.4 | 1.7e-27 | 1.0e-26 | |
| KEGG_PATHWAY | hsa04110:Cell cycle | 89 | 4.8 | 2.4e-27 | 1.4e-26 | |
| KEGG_PATHWAY | hsa04261:Adrenergic signaling in cardiomyocytes | 98 | 5.3 | 3.2e-27 | 1.9e-26 | |
| KEGG_PATHWAY | hsa04810:Regulation of actin cytoskeleton | 125 | 6.7 | 4.9e-27 | 2.8e-26 | |
| KEGG_PATHWAY | hsa04022:cGMP-PKG signaling pathway | 105 | 5.6 | 7.8e-27 | 4.4e-26 | |
| KEGG_PATHWAY | hsa04917:Prolactin signaling pathway | 61 | 3.3 | 9.8e-27 | 5.4e-26 | |
| KEGG_PATHWAY | hsa04919:Thyroid hormone signaling pathway | 82 | 4.4 | 3.7e-26 | 2.0e-25 | |
| KEGG_PATHWAY | hsa05212:Pancreatic cancer | 57 | 3.1 | 2.9e-25 | 1.6e-24 | |
| KEGG_PATHWAY | hsa04071:Sphingolipid signaling pathway | 79 | 4.2 | 9.8e-25 | 5.1e-24 | |
| KEGG_PATHWAY | hsa04916:Melanogenesis | 73 | 3.9 | 1.7e-24 | 8.4e-24 | |
| KEGG_PATHWAY | hsa04068:FoxO signaling pathway | 88 | 4.7 | 3.3e-24 | 1.6e-23 | |
| KEGG_PATHWAY | hsa04650:Natural killer cell mediated cytotoxicity | 79 | 4.2 | 4.0e-23 | 1.9e-22 | |
| KEGG_PATHWAY | hsa05210:Colorectal cancer | 53 | 2.9 | 2.1e-22 | 1.0e-21 | |
| KEGG_PATHWAY | hsa04540:Gap junction | 63 | 3.4 | 1.7e-21 | 7.8e-21 | |
| KEGG_PATHWAY | hsa04662:B cell receptor signaling pathway | 55 | 3.0 | 4.6e-21 | 2.2e-20 | |
| KEGG_PATHWAY | hsa04370:VEGF signaling pathway | 50 | 2.7 | 8.2e-21 | 3.8e-20 | |
| KEGG_PATHWAY | hsa04064:NF-kappa B signaling pathway | 63 | 3.4 | 1.3e-20 | 6.0e-20 | |
| KEGG_PATHWAY | hsa05222:Small cell lung cancer | 63 | 3.4 | 1.3e-20 | 6.0e-20 | |
| KEGG_PATHWAY | hsa04931:Insulin resistance | 73 | 3.9 | 1.9e-20 | 8.6e-20 | |
| KEGG_PATHWAY | hsa04750:Inflammatory mediator regulation of TRP channels | 66 | 3.6 | 2.5e-20 | 1.1e-19 | |
| KEGG_PATHWAY | hsa04210:Apoptosis | 51 | 2.7 | 4.0e-20 | 1.7e-19 | |
| KEGG_PATHWAY | hsa04622:RIG-I-like receptor signaling pathway | 54 | 2.9 | 5.1e-20 | 2.2e-19 | |
| KEGG_PATHWAY | hsa04921:Oxytocin signaling pathway | 91 | 4.9 | 7.2e-20 | 3.0e-19 | |
| KEGG_PATHWAY | hsa05223:Non-small cell lung cancer | 47 | 2.5 | 7.4e-20 | 3.0e-19 | |
| KEGG_PATHWAY | hsa04611:Platelet activation | 80 | 4.3 | 1.8e-19 | 7.3e-19 | |
| KEGG_PATHWAY | hsa04310:Wnt signaling pathway | 83 | 4.5 | 1.2e-18 | 4.8e-18 | |
| KEGG_PATHWAY | hsa05211:Renal cell carcinoma | 49 | 2.6 | 1.5e-18 | 5.8e-18 | |
| KEGG_PATHWAY | hsa05218:Melanoma | 53 | 2.9 | 4.7e-18 | 1.8e-17 | |
| KEGG_PATHWAY | hsa05031:Amphetamine addiction | 49 | 2.6 | 5.0e-18 | 1.9e-17 | |
| KEGG_PATHWAY | hsa04664:Fc epsilon RI signaling pathway | 51 | 2.7 | 5.1e-18 | 1.9e-17 | |
| KEGG_PATHWAY | hsa04390:Hippo signaling pathway | 85 | 4.6 | 8.1e-17 | 4.4e-16 | |
| KEGG_PATHWAY | hsa04670:Leukocyte transendothelial migration | 71 | 3.8 | 1.1e-16 | 4.4e-16 | |
| KEGG_PATHWAY | hsa05100:Bacterial invasion of epithelial cells | 51 | 2.7 | 3.1e-16 | 1.2e-15 | |
| KEGG_PATHWAY | hsa05146:Amoebiasis | 66 | 3.6 | 1.0e-15 | 3.6e-15 | |
| KEGG_PATHWAY | hsa04666:Fc gamma R-mediated phagocytosis | 55 | 3.0 | 2.7e-15 | 9.2e-15 | |
| KEGG_PATHWAY | hsa04066:HIF-1 signaling pathway | 61 | 3.3 | 3.2e-15 | 1.1e-14 | |
| KEGG_PATHWAY | hsa04520:Adherens junction | 48 | 2.6 | 3.4e-15 | 1.2e-14 | |
| KEGG_PATHWAY | hsa04730:Long-term depression | 43 | 2.3 | 5.1e-15 | 1.7e-14 | |
| KEGG_PATHWAY | hsa04723:Retrograde endocannabinoid signaling | 60 | 3.2 | 8.5e-15 | 2.8e-14 | |
| KEGG_PATHWAY | hsa04923:Regulation of lipolysis in adipocytes | 42 | 2.3 | 1.5e-14 | 5.0e-14 | |
| KEGG_PATHWAY | hsa05133:Pertussis | 50 | 2.7 | 3.5e-14 | 1.1e-13 | |
| KEGG_PATHWAY | hsa04925:Aldosterone synthesis and secretion | 52 | 2.8 | 5.3e-14 | 1.7e-13 | |
| KEGG_PATHWAY | hsa04550:Signaling pathways regulating pluripotency of stem cells | 76 | 4.1 | 6.7e-14 | 2.1e-13 | |
| KEGG_PATHWAY | hsa04060:Cytokine-cytokine receptor interaction | 108 | 5.8 | 9.8e-14 | 3.0e-13 | |
| KEGG_PATHWAY | hsa04152:AMPK signaling pathway | 69 | 3.7 | 1.9e-13 | 5.7e-13 | |
| KEGG_PATHWAY | hsa05219:Bladder cancer | 33 | 1.8 | 4.2e-13 | 1.3e-12 | |
| KEGG_PATHWAY | hsa04918:Thyroid hormone synthesis | 45 | 2.4 | 4.7e-13 | 1.4e-12 | |
| KEGG_PATHWAY | hsa04922:Glucagon signaling pathway | 57 | 3.1 | 5.2e-13 | 1.5e-12 | |
| KEGG_PATHWAY | hsa05131:Shigellosis | 44 | 2.4 | 5.6e-13 | 1.6e-12 | |
| KEGG_PATHWAY | hsa05231:Choline metabolism in cancer | 56 | 3.0 | 6.8e-13 | 2.0e-12 | |
| KEGG_PATHWAY | hsa05034:Alcoholism | 72 | 3.9 | 2.7e-12 | 7.7e-12 | |
| KEGG_PATHWAY | hsa05140:Leishmaniasis | 45 | 2.4 | 5.1e-12 | 1.4e-11 | |
| KEGG_PATHWAY | hsa04724:Glutamatergic synapse | 61 | 3.3 | 9.9e-12 | 2.8e-11 | |
| KEGG_PATHWAY | hsa04621:NOD-like receptor signaling pathway | 38 | 2.0 | 2.0e-11 | 5.5e-11 | |
| KEGG_PATHWAY | hsa05014:Amyotrophic lateral sclerosis (ALS) | 36 | 1.9 | 2.7e-11 | 7.5e-11 | |
| KEGG_PATHWAY | hsa04150:mTOR signaling pathway | 39 | 2.1 | 3.8e-11 | 1.0e-10 | |
| KEGG_PATHWAY | hsa04971:Gastric acid secretion | 44 | 2.4 | 5.6e-11 | 1.5e-10 | |
| KEGG_PATHWAY | hsa05032:Morphine addiction | 49 | 2.6 | 3.3e-10 | 8.6e-10 | |
| KEGG_PATHWAY | hsa05216:Thyroid cancer | 24 | 1.3 | 3.5e-10 | 9.3e-10 | |
| KEGG_PATHWAY | hsa05202:Transcriptional misregulation in cancer | 74 | 4.0 | 5.5e-10 | 1.4e-9 | |
| KEGG_PATHWAY | hsa05030:Cocaine addiction | 33 | 1.8 | 6.1e-10 | 1.6e-9 | |
| KEGG_PATHWAY | hsa04144:Endocytosis | 102 | 5.5 | 1.1e-9 | 2.7e-9 | |
| KEGG_PATHWAY | hsa04530:Tight junction | 65 | 3.5 | 1.2e-9 | 3.1e-9 | |
| KEGG_PATHWAY | hsa04020:Calcium signaling pathway | 81 | 4.4 | 1.6e-9 | 3.9e-9 | |
| KEGG_PATHWAY | hsa04115:p53 signaling pathway | 40 | 2.2 | 2.2e-9 | 5.4e-9 | |
| KEGG_PATHWAY | hsa04911:Insulin secretion | 48 | 2.6 | 2.2e-9 | 5.5e-9 | |
| KEGG_PATHWAY | hsa04270:Vascular smooth muscle contraction | 58 | 3.1 | 3.0e-9 | 7.2e-9 | |
| KEGG_PATHWAY | hsa04726:Serotonergic synapse | 54 | 2.9 | 4.2e-9 | 1.0e-8 | |
| KEGG_PATHWAY | hsa05120:Epithelial cell signaling in Helicobacter pylori infection | 39 | 2.1 | 5.3e-9 | 1.3e-8 | |
| KEGG_PATHWAY | hsa04960:Aldosterone-regulated sodium reabsorption | 28 | 1.5 | 7.8e-9 | 1.9e-8 | |
| KEGG_PATHWAY | hsa05230:Central carbon metabolism in cancer | 37 | 2.0 | 1.7e-8 | 4.0e-8 | |
| KEGG_PATHWAY | hsa04924:Renin secretion | 36 | 1.9 | 2.2e-8 | 5.2e-8 | |
| KEGG_PATHWAY | hsa04612:Antigen processing and presentation | 38 | 2.0 | 2.3e-8 | 5.3e-8 | |
| KEGG_PATHWAY | hsa04350:TGF-beta signaling pathway | 44 | 2.4 | 3.3e-8 | 7.6e-8 | |
| KEGG_PATHWAY | hsa05132:Salmonella infection | 44 | 2.4 | 3.3e-8 | 7.6e-8 | |
| KEGG_PATHWAY | hsa04930:Type II diabetes mellitus | 31 | 1.7 | 4.3e-8 | 9.7e-8 | |
| KEGG_PATHWAY | hsa04970:Salivary secretion | 41 | 2.2 | 1.3e-7 | 3.0e-7 | |
| KEGG_PATHWAY | hsa04727:GABAergic synapse | 44 | 2.4 | 1.4e-7 | 3.0e-7 | |
| KEGG_PATHWAY | hsa04360:Axon guidance | 57 | 3.1 | 2.0e-7 | 4.4e-7 | |
| KEGG_PATHWAY | hsa05144:Malaria | 29 | 1.6 | 2.7e-7 | 6.0e-7 | |
| KEGG_PATHWAY | hsa05134:Legionellosis | 31 | 1.7 | 3.0e-7 | 6.4e-7 | |
| KEGG_PATHWAY | hsa04932:Non-alcoholic fatty liver disease (NAFLD) | 63 | 3.4 | 3.4e-7 | 7.2e-7 | |
| KEGG_PATHWAY | hsa05321:Inflammatory bowel disease (IBD) | 35 | 1.9 | 4.9e-7 | 1.0e-6 | |
| KEGG_PATHWAY | hsa04920:Adipocytokine signaling pathway | 38 | 2.0 | 5.3e-7 | 1.1e-6 | |
| KEGG_PATHWAY | hsa04140:Regulation of autophagy | 25 | 1.3 | 7.5e-7 | 1.6e-6 | |
| KEGG_PATHWAY | hsa05143:African trypanosomiasis | 22 | 1.2 | 1.5e-6 | 3.1e-6 | |
| KEGG_PATHWAY | hsa05010:Alzheimer's disease | 62 | 3.3 | 1.5e-6 | 3.1e-6 | |
| KEGG_PATHWAY | hsa04623:Cytosolic DNA-sensing pathway | 32 | 1.7 | 2.0e-6 | 4.1e-6 | |
| KEGG_PATHWAY | hsa05020:Prion diseases | 22 | 1.2 | 3.1e-6 | 6.4e-6 | |
| KEGG_PATHWAY | hsa05320:Autoimmune thyroid disease | 28 | 1.5 | 6.6e-6 | 1.3e-5 | |
| KEGG_PATHWAY | hsa04972:Pancreatic secretion | 39 | 2.1 | 1.6e-5 | 3.1e-5 | |
| KEGG_PATHWAY | hsa05416:Viral myocarditis | 29 | 1.6 | 2.1e-5 | 4.1e-5 | |
| KEGG_PATHWAY | hsa04640:Hematopoietic cell lineage | 38 | 2.0 | 2.1e-5 | 4.2e-5 | |
| KEGG_PATHWAY | hsa05130:Pathogenic Escherichia coli infection | 27 | 1.5 | 2.4e-5 | 4.7e-5 | |
| KEGG_PATHWAY | hsa05217:Basal cell carcinoma | 29 | 1.6 | 3.2e-5 | 6.3e-5 | |
| KEGG_PATHWAY | hsa04320:Dorso-ventral axis formation | 15 | 0.8 | 7.0e-5 | 0.00013 | |
| KEGG_PATHWAY | hsa04120:Ubiquitin mediated proteolysis | 53 | 2.9 | 0.00014 | 0.00028 | |
| KEGG_PATHWAY | hsa04961:Endocrine and other factor-regulated calcium reabsorption | 24 | 1.3 | 0.00015 | 0.00029 | |
| KEGG_PATHWAY | hsa05414:Dilated cardiomyopathy | 37 | 2.0 | 0.0002 | 0.00037 | |
| KEGG_PATHWAY | hsa04512:ECM-receptor interaction | 38 | 2.0 | 0.00026 | 0.00049 | |
| KEGG_PATHWAY | hsa05340:Primary immunodeficiency | 19 | 1.0 | 0.00028 | 0.00051 | |
| KEGG_PATHWAY | hsa04962:Vasopressin-regulated water reabsorption | 22 | 1.2 | 0.00043 | 0.00079 | |
| KEGG_PATHWAY | hsa05323:Rheumatoid arthritis | 35 | 1.9 | 0.0008 | 0.0015 | |
| KEGG_PATHWAY | hsa05332:Graft-versus-host disease | 17 | 0.9 | 0.0013 | 0.0024 | |
| KEGG_PATHWAY | hsa04913:Ovarian steroidogenesis | 23 | 1.2 | 0.0014 | 0.0025 | |
| KEGG_PATHWAY | hsa05330:Allograft rejection | 18 | 1.0 | 0.0022 | 0.004 | |
| KEGG_PATHWAY | hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 29 | 1.6 | 0.0042 | 0.0074 | |
| KEGG_PATHWAY | hsa04940:Type I diabetes mellitus | 19 | 1.0 | 0.0048 | 0.0084 | |
| KEGG_PATHWAY | hsa04141:Protein processing in endoplasmic reticulum | 54 | 2.9 | 0.0049 | 0.0086 | |
| KEGG_PATHWAY | hsa04340:Hedgehog signaling pathway | 14 | 0.8 | 0.0053 | 0.0093 | |
| KEGG_PATHWAY | hsa04710:Circadian rhythm | 15 | 0.8 | 0.0084 | 0.015 | |
| KEGG_PATHWAY | hsa04145:Phagosome | 49 | 2.6 | 0.014 | 0.023 | |
| KEGG_PATHWAY | hsa03015:mRNA surveillance pathway | 31 | 1.7 | 0.019 | 0.033 | |
| KEGG_PATHWAY | hsa04976:Bile secretion | 24 | 1.3 | 0.024 | 0.04 | |
| KEGG_PATHWAY | hsa05110:Vibrio cholerae infection | 19 | 1.0 | 0.038 | 0.064 | |
| KEGG_PATHWAY | hsa04330:Notch signaling pathway | 19 | 1.0 | 0.038 | 0.064 | |
| KEGG_PATHWAY | hsa04672:Intestinal immune network for IgA production | 18 | 1.0 | 0.041 | 0.067 | |
| KEGG_PATHWAY | hsa04973:Carbohydrate digestion and absorption | 16 | 0.9 | 0.045 | 0.074 | |
| KEGG_PATHWAY | hsa04070:Phosphatidylinositol signaling system | 30 | 1.6 | 0.052 | 0.085 |